SFBC Anapharm announces the nomination of Ms. Isabel Desmarais as Assistant Chief Operating Officer
Ms Johane Boucher-Champagne, SFBC Anapharm’s Chief Operating Officer, is happy to announce the nomination of Ms Isabel Desmarais as Assistant Chief Operating Officer.
QUEBEC, May 6, 2005 -- Ms Johane Boucher-Champagne, SFBC Anapharm's Chief Operating Officer, is happy to announce the nomination of Ms Isabel Desmarais as Assistant Chief Operating Officer. Graduated in Pharmacy at the Universit Laval in 1995, Ms Desmarais also holds a Master in Hospital Pharmacy and a MBA in Business Management, completed in 2003 while working at SFBC Anapharm.
"Her expertise, her professionalism and her large contribution to SFBC Anapharm's business makes her the ideal candidate for this newly created job within our general management team. The dazzling expansion of our organization during the last years and the numerous challenges we have to face require excellence. I am therefore very happy to rely on such a quality person to help us in taking them up", declared Ms Boucher-Champagne
Since she joined SFBC Anapharm in 1998, Isabel Desmarais quickly got promotions within the company, being first a protocol writer, then a project manager and assistant director in our Scientific and Regulatory Affairs division. Having a strong 10-year experience in the pharmaceutical field, Isabel Desmarais has been acting as Project Management Director for 3 years at SFBC Anapharm, where she greatly contributed to the elaboration and development of many efficient and fast management programs and procedures for all critical aspects of studies and this, while respecting the highest quality standards.
Founded in Quebec in 1994, Anapharm, member of SFBC International, is the most important private contract research organisation specialized in phases I & II and bioequivalence tests in North America. The company offers leading services to pharmaceutical and biopharmaceutical companies all over the world. The company employs more than 700 specialists located in four sites in Quebec, its head office, in Montreal, Trois-Rivires and Toronto.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
